Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;85(2):165-71.
doi: 10.4065/mcp.2009.0314.

Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency

Ayman A El-Menyar  1 , Jassim Al Suwaidi, David R Holmes Jr
Affiliations
Review

Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency

Ayman A El-Menyar et al. Mayo Clin Proc. 2010 Feb.

Abstract

Renal insufficiency (RI) has been shown to be associated with increased major adverse cardiovascular events after percutaneous coronary intervention. We reviewed the impact of RI on the pathogenesis of coronary artery disease and outcomes after percutaneous coronary intervention in the form of drug-eluting stent (DES) implantation in these high-risk patients. We searched the English-language literature indexed in MEDLINE, Scopus, and EBSCO Host research databases from 1990 through January 2009, using as search terms coronary revascularization, drug-eluting stent, and renal insufficiency. Studies that assessed DES implantation in patients with various degrees of RI were selected for review. Most of the available data were extracted from observational studies, and data from randomized trials formed the basis of a post hoc analysis. The outcomes after coronary revascularization were less favorable in patients with RI than in those with normal renal function. In patients with RI, DES implantation yielded better outcomes than did use of bare-metal stents. Randomized trials are needed to define optimal treatment of these high-risk patients with coronary artery disease.

PubMed Disclaimer

References

    1. Best PJ, Berger PB, Davis BR, et al. PRESTO Investigators Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol. 2004;44(9):1786-1791 - PubMed
    1. Zhang RY, Zhu ZB, Zhang Q, et al. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol. 2009;136(1):72-79 - PubMed
    1. Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol. 2005;95(2):167-172 - PubMed
    1. Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Am Heart J. 2005;150(6):1163-1170 - PubMed
    1. Zhang RY, Ni JW, Zhang JS, et al. Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. Chin Med J (Engl) 2006;119(14):1176-1181 - PubMed

MeSH terms